Shopping Cart
Remove All
Your shopping cart is currently empty
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $55 | In Stock | In Stock | |
| 2 mg | $82 | In Stock | In Stock | |
| 5 mg | $136 | In Stock | In Stock | |
| 10 mg | $198 | In Stock | In Stock | |
| 25 mg | $331 | In Stock | In Stock | |
| 50 mg | $451 | - | In Stock | |
| 100 mg | $595 | - | In Stock | |
| 500 mg | $1,180 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $151 | In Stock | In Stock |
| Description | PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model. |
| In vitro | PD-1/PD-L1-IN-9 (46.9-1500 nM; pretreated for 2 h) enhances the antitumor immunity of PBMCs against MDB-MB 231 cells in a dose-dependent manner, with an EC50 of approximately 100 nM[1]. |
| In vivo | PD-1/PD-L1-IN-9 (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner without causing body weight loss or mortality in mice. PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits a half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg), and Cmax (1233 ng/mL) in rats. PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) shows moderate oral bioavailability (F=22%), half-life (t1/2=6.4 h), and Cmax (192 ng/mL) in rats[1]. |
| Molecular Weight | 348.44 |
| Formula | C22H24N2O2 |
| Cas No. | 2628506-54-5 |
| Smiles | COc1nc(ccc1CNCCO)-c1cccc(c1C)-c1ccccc1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (258.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (9.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.